Michael R. Hayden
Affiliations: | University of British Columbia, Vancouver, Vancouver, BC, Canada |
Area:
Biostatistics BiologyGoogle:
"Michael Hayden"Mean distance: (not calculated yet)
Cross-listing: MathTree
Children
Sign in to add trainee| Katherine J. Ashbourne Excoffon | grad student | 2000 | UBC (MathTree) |
| Susanne M. Clee | grad student | 2001 | UBC (MathTree) |
| Ryan R. Brinkman | grad student | 2002 | UBC (MathTree) |
| Elizabeth J. Slow | grad student | 2005 | UBC (MathTree) |
| Jeremy M. Van Raamsdonk | grad student | 2005 | UBC |
| Rona K. Graham | grad student | 2000-2006 | University of Sherbrooke (Canada) |
| Mahmoud A. Pouladi | grad student | 2003-2010 | UBC |
| Jeffrey B. Carroll | grad student | 2004-2010 | Western Washington University |
| Alicia Semaka | grad student | 2006-2012 | UBC |
| Amber L. Southwell | post-doc | 2009-2016 | UBC |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Sogorb-Gonzalez M, Landles C, Caron NS, et al. (2024) Exon 1-targeting miRNA reduces the pathogenic exon 1 HTT protein in Huntington disease models. Brain : a Journal of Neurology |
| Bartl S, Xie Y, Potluri N, et al. (2024) Corrigendum to "Reducing huntingtin by immunotherapy delays disease progression in a mouse model of Huntington disease" [Neurobiology of Disease, 2024 Jan:190:106376]. Neurobiology of Disease. 106444 |
| Caron NS, Aly AE, Black HF, et al. (2024) Systemic delivery of mutant huntingtin lowering antisense oligonucleotides to the brain using apolipoprotein A-I nanodisks for Huntington disease. Journal of Controlled Release : Official Journal of the Controlled Release Society |
| Bartl S, Xie Y, Potluri N, et al. (2023) Reducing huntingtin by immunotherapy delays disease progression in a mouse model of Huntington disease. Neurobiology of Disease. 106376 |
| Duarte F, Vachey G, Caron NS, et al. (2023) Limitations of dual-sgRNA CRISPR strategies for the treatment of CNS genetic disorders. Human Gene Therapy |
| Van Raamsdonk JM, Al-Shekaili HH, Wagner L, et al. (2023) Huntingtin Decreases Susceptibility to a Spontaneous Seizure Disorder in FVN/B Mice. Aging and Disease |
| Joachimiak P, Ciesiołka A, Kozłowska E, et al. (2023) Allele-specific quantitation of ATXN3 and HTT transcripts in polyQ disease models. Bmc Biology. 21: 17 |
| Chan LL, Hill A, Lu G, et al. (2022) Huntingtin Overexpression Does Not Alter Overall Survival in Murine Cancer Models. Journal of Huntington's Disease |
| Caron NS, Banos R, Aly AE, et al. (2022) Cerebrospinal fluid mutant huntingtin is a biomarker for huntingtin lowering in the striatum of Huntington disease mice. Neurobiology of Disease. 166: 105652 |
| Bhattacharyya A, Trotta CR, Narasimhan J, et al. (2021) Small molecule splicing modifiers with systemic HTT-lowering activity. Nature Communications. 12: 7299 |